Text Version |Site map | Contact Us | Temple University | FAQs | Search
Prospective Students | Current Students | Faculty/Preceptors | Alumni

Why Temple School of Pharmacy

Read more...
cGMP Services
cGMP Services
Moulder Center
QA/RA

Faculty & Staff Directory

 

 

 

Benjamin Blass

Assistant Professor of Medicinal Chemistry, Moulder Center

 

3307 N. Broad Street

Philadelphia, PA 19140

office Room 544

phone (215) 707-1085

email benjamin.blass@temple.edu

 

 

Biosketch | Patents and Patent Applications
Publications and Presentations | Invited Lectures

 

Biosketch

 

Dr. Blass received his B.S. in Chemistry from Emory University in 1990 and his Ph.D. in Organic Chemistry in 1994 from the University of Rochester under the direction of Andrew S. Kende.  Upon completion of his doctoral program, Dr. Blass pursued a career in drug discovery and development with Procter & Gamble Pharmaceuticals (Cincinnati, OH 1994-2006) and Wyeth Research (2006-2010).   Over the course of his industrial career, Dr. Blass conducted research on a wide range of disease states through the careful application of medicinal chemistry strategy and drug design principles.  He and his research teams produced novel chemical matter to address chronic pain, inflammation, cancer, amyotrophic lateral sclerosis, diabetes, osteoporosis, obesity, arthritis, heart failure, peripheral artery disease, acute coronary syndrome, and atrial fibrillation, producing multiple pre-clinical and clinical candidates.  He is the principle author or co-author on fifty patents, publications, and invited lectureships and is registered with the United States Patent and Trademark Office as patent agent.

 

Patents and Patent Applications:


  1. Kv1.5 potassium channel inhibitors, Janusz, J. M.; Hodson, S. J.; Bosch G. K.; White R. E.; Blass B. E.; Jackson C. M.; Fairweather, N. T. US Patent 7803827, 2010.
  2. Preparation of 4-imidazolidinones as Kv1.5 potassium channel inhibitors, Blass, B. E.; Janusz, J. M.; Wu, S.; Ridgeway, J. M.; Coburn, K.; Lee, W.; Fluxe, A. J.; White, R. E.; Jackson, C. M.; Fairweather, N. WO 2009079624, 2009.
  3. Preparation of 4-imidazolidinones as Kv1.5 potassium channel inhibitors, Blass, B. E.; Janusz, J. M.; Ridgeway, J. M.; Wu, S. WO 2009079630, 2009.
  4. Kv1.5 potassium channel inhibitors, Janusz, J. M.; Hodson, S. J.; Bosch G. K.; White R. E.; Blass B. E.; Jackson C. M.; Fairweather, N. T. US Patent 7504517, 2009.
  5. Preparation of 4-oxo-1,3,8-triaza-spiro[4.5]decanes as Kv1.5 potassium channel inhibitors, Janusz, J. M.; Wu, S.; Fairweather, N. T.; Lee, W.; Blass, B. E.; Fluxe, A. J.; Hodson, S. J.; Ridgeway, J. M. WO  2007149873, 2007.
  6. Imidazolidinone derivatives as Kv1.5 potassium channel inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cardiac arrhythmia, Janusz, J. M.; Hodson, S. J.; Bosch, G. K.; White, R. E.; Blass, B. E.; Jackson, C. M.; Fairweather, N. T. WO 2007149874, 2007.
  7. Triazole compounds useful in treating diseases associated with unwanted cytokine activity, Tullis, J S.; Van Rens, J. C.; Clark, M. P.; Blass, B. E.; Natchus, M. G.; De, B. US Patent 6787555, 2004.
  8. Triazole compounds useful in treating diseases associated with unwanted cytokine activity, Tullis, J S.; Van Rens, J. C.; Clark, M. P.; Blass, B. E.; Natchus, M. G.; De, B. US Patent 6727364, 2004.
  9. Process for making functionalized oxazolidinone compounds, Blass, B. E. US Patent 6635769, 2003.
  10. N-(1-Phenylethyl)-5-phenyl-imidazole-2-amine compounds, their composition and uses, Blass, B. E.; Liu, S.; Portlock, D. E. US Patent 6596739, 2003.
  11. Preparation of 4-aryltriazoles useful in treating diseases associated with unwanted cytokine activity, Tullis, J S.; Van Rens, J. C.; Clark, M. P.; Blass, B. E.; Natchus, M. G.; De, B. WO 200288113, 2002.
  12. Preparation of 4-aryltriazoles useful in treating diseases associated with unwanted cytokine Activity, Tullis, J S.; Van Rens, J. C.; Clark, M. P.; Blass, B. E.; Natchus, M. G.; De, B. WO 200288108, 2002.
  13. N-(1-Phenylethyl)-5-phenyl-imidazole-2-amine compounds for treating cardiovascular, oncology, infectious and inflammatory diseases.  Liu, S.; Blass, B.E.; Portlock, D.E. WO 0144203, 2001.
  14. Process for selective alkylation of benzodiazepin-2,5-dione compounds in the presence of KF/Al2O3 Blass, B.E.; Liu, S. WO 0130769, 2001.
  15. Process for making functionalized oxazolidinone compounds in the presence of KF/Al2O3 Blass, B.E. WO 0069837, 2000.